Near 15% Weight Loss With Novel Oral GLP-1 RA in Phase II Obesity Trial
(MedPage Today) -- SAN DIEGO -- Orforglipron, an investigational nonpeptide GLP-1 receptor agonist, helped people with obesity lose a significant amount of weight in a phase II trial.
Tested at four once-daily doses -- 12, 24, 36, or 45 mg...
Source: MedPage Today Cardiovascular - Category: Cardiology Source Type: news
More News: Cardiology | Cardiovascular | Eating Disorders & Weight Management | Heart | Obesity | Weight Loss